tiprankstipranks
Trending News
More News >
Medicenna Therapeutics (MDNAF)
:MDNAF
US Market

Medicenna Therapeutics Corp (MDNAF) Stock Forecast & Price Target

Compare
224 Followers
See the Price Targets and Ratings of:

MDNAF Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Medicenna
Therapeutics Corp
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDNAF Stock 12 Month Forecast

Average Price Target

$4.38
▲(534.12%Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Medicenna Therapeutics Corp in the last 3 months. The average price target is $4.38 with a high forecast of $6.01 and a low forecast of $2.74. The average price target represents a 534.12% change from the last price of $0.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.00710101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.37545238,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.74380375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Nov<br/>2023","9":"Aug<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.68,1.089777000769231,1.4995540015384616,1.9093310023076926,2.3191080030769236,2.7288850038461545,3.138662004615385,3.548439005384616,3.958216006153847,4.3679930069230775,4.777770007692308,5.187547008461539,5.5973240092307694,{"y":6.00710101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.68,0.9642655676923078,1.2485311353846154,1.5327967030769232,1.8170622707692305,2.1013278384615384,2.385593406153846,2.6698589738461536,2.9541245415384614,3.238390109230769,3.5226556769230766,3.8069212446153844,4.091186812307692,{"y":4.37545238,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.68,0.8387541346153846,0.9975082692307693,1.156262403846154,1.3150165384615384,1.473770673076923,1.6325248076923078,1.7912789423076925,1.9500330769230771,2.108787211538462,2.2675413461538465,2.4262954807692307,2.5850496153846154,{"y":2.74380375,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.293,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.293,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.293,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.293,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.293,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.293,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.293,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.01Average Price Target$4.38Lowest Price Target$2.74
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton Analyst forecast on MDNAF
David Martin PhDBloom Burton
Bloom Burton
$6
Buy
769.57%
Upside
Reiterated
04/29/25
Promising Clinical Trial Results Boost Buy Rating for Medicenna Therapeutics Corp
Research Capital Analyst forecast on MDNAF
Andre UddinResearch Capital
Research Capital
$2.74
Buy
297.32%
Upside
Reiterated
04/28/25
Medicenna Therapeutics has elegant science, Research Capital saysUddin said the data strengthens the case for MDNA11 as a leading next-generation IL-2 therapy in solid tumours.
H.C. Wainwright Analyst forecast on MDNAF
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$2.5
Buy
262.32%
Upside
Reiterated
12/06/24
H.C. Wainwright reiterates Buy Rating on Medicenna Therapeutics (MDNA)H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).
JonesTrading Analyst forecast on MDNAF
Catherine NovackJonesTrading
JonesTrading
$3.66
Buy
429.76%
Upside
Reiterated
12/05/24
We believe the futility hurdle in r/r anal cancer is ORR of >20%. Prior clinical trials evaluating CPIs in anal cancer have shown ORR of 10-14% [S.Rao, J.-P.Spano, et al. ESMO Open. 2022, Vol. 7(4); A. Marabelle, J.-P. Delord, et al. Lancet, 2022, Vol. 7(5); S. Lonardi, F. Pietrantonio, et al. J Immunother Cancer. 2021, Vol. 9(11)].
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton Analyst forecast on MDNAF
David Martin PhDBloom Burton
Bloom Burton
$6
Buy
769.57%
Upside
Reiterated
04/29/25
Promising Clinical Trial Results Boost Buy Rating for Medicenna Therapeutics Corp
Research Capital Analyst forecast on MDNAF
Andre UddinResearch Capital
Research Capital
$2.74
Buy
297.32%
Upside
Reiterated
04/28/25
Medicenna Therapeutics has elegant science, Research Capital saysUddin said the data strengthens the case for MDNA11 as a leading next-generation IL-2 therapy in solid tumours.
H.C. Wainwright Analyst forecast on MDNAF
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$2.5
Buy
262.32%
Upside
Reiterated
12/06/24
H.C. Wainwright reiterates Buy Rating on Medicenna Therapeutics (MDNA)H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).
JonesTrading Analyst forecast on MDNAF
Catherine NovackJonesTrading
JonesTrading
$3.66
Buy
429.76%
Upside
Reiterated
12/05/24
We believe the futility hurdle in r/r anal cancer is ORR of >20%. Prior clinical trials evaluating CPIs in anal cancer have shown ORR of 10-14% [S.Rao, J.-P.Spano, et al. ESMO Open. 2022, Vol. 7(4); A. Marabelle, J.-P. Delord, et al. Lancet, 2022, Vol. 7(5); S. Lonardi, F. Pietrantonio, et al. J Immunother Cancer. 2021, Vol. 9(11)].
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medicenna Therapeutics Corp

1 Month
xxx
Success Rate
4/8 ratings generated profit
50%
Average Return
+20.20%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +20.20% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+58.86%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +58.86% per trade.
1 Year
Andre UddinResearch Capital
Success Rate
6/8 ratings generated profit
75%
Average Return
+205.26%
reiterated a buy rating 2 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +205.26% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+28.10%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +28.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDNAF Analyst Recommendation Trends

Rating
Apr 24
Aug 24
Nov 24
Dec 24
Apr 25
Strong Buy
5
3
3
3
5
Buy
1
2
2
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
5
5
5
6
In the current month, MDNAF has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MDNAF average Analyst price target in the past 3 months is 4.38.
Each month's total comprises the sum of three months' worth of ratings.

MDNAF Financial Forecast

MDNAF Earnings Forecast

Next quarter’s earnings estimate for MDNAF is -$0.04 with a range of -$0.05 to -$0.04. The previous quarter’s EPS was -$0.05. MDNAF beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year MDNAF has Outperformed its overall industry.
Next quarter’s earnings estimate for MDNAF is -$0.04 with a range of -$0.05 to -$0.04. The previous quarter’s EPS was -$0.05. MDNAF beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year MDNAF has Outperformed its overall industry.
No data currently available

MDNAF Sales Forecast

Next quarter’s sales forecast for MDNAF is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MDNAF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year MDNAF has Preformed in-line its overall industry.
Next quarter’s sales forecast for MDNAF is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MDNAF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year MDNAF has Preformed in-line its overall industry.

MDNAF Stock Forecast FAQ

What is MDNAF’s average 12-month price target, according to analysts?
Based on analyst ratings, Medicenna Therapeutics’s 12-month average price target is 4.38.
    What is MDNAF’s upside potential, based on the analysts’ average price target?
    Medicenna Therapeutics has 534.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MDNAF a Buy, Sell or Hold?
          Medicenna Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Medicenna Therapeutics’s price target?
            The average price target for Medicenna Therapeutics is 4.38. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.01 ,the lowest forecast is $2.74. The average price target represents 534.12% Increase from the current price of $0.69.
              What do analysts say about Medicenna Therapeutics?
              Medicenna Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of MDNAF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis